Helix BioPharma (TSE:HBP) Stock Crosses Below 50-Day Moving Average – Should You Sell?

Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s share price passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.50 and traded as low as C$0.94. Helix BioPharma shares last traded at C$0.96, with a volume of 8,389 shares traded.

Helix BioPharma Stock Up 4.3%

The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.03 and a current ratio of 0.45. The firm has a market cap of C$73.32 million, a price-to-earnings ratio of -24.00 and a beta of 1.15. The business’s 50 day moving average price is C$1.50 and its 200 day moving average price is C$1.58.

Helix BioPharma Company Profile

(Get Free Report)

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

Further Reading

• Five stocks we like better than Helix BioPharma
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs